Skip to main content
NIH funding notice PAR-18-632

NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)

Closed on January 13, 2021.

Posted
February 6, 2018
Close date
January 13, 2021
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

6 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,481,298 in first-year total cost, median $299,378.

Most frequent study sections

  1. Special Emphasis Panel[ZAI1 MFH-M (M1)]2
  2. Special Emphasis Panel[ZAI1 GPJ-M (M1)]1
  3. Special Emphasis Panel[ZAI1 JBS-A (J1)]1
  4. Special Emphasis Panel[ZAI1 KGH-I (M1)]1
  5. Special Emphasis Panel[ZAI1 PTM-I (J3)]1

Most frequent institutions

  1. NAJIT TECHNOLOGIES, INC.2
  2. IMMUNOGENICS, LLC1
  3. NAVIGEN, INC.1
  4. NEXEOS DIAGNOSTICS, INC.1
  5. TRELLIS BIOSCIENCE, INC.1
Competing awards under PAR-18-632 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2020A Phase Ia/Ib Clinical Study of HIV Entry Inhibitor CPT31:Single and Multiple Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults anAdults with HIV2U44AI095172-08MUELLER, ALAN LNAVIGEN, INC., UT$1,000,000ZAI1
2020Novel, Non-InvasiveImaging of Eosinophil-Related Inflammation Throughout the Esophagus in Patients withEosinophilic Esophagitis1U44AI152966-01GLEICH, GERALD JNEXEOS DIAGNOSTICS, INC., PA$299,982ZAI1
2020HCMV Therapeutic Antibody Safety Trial1U44AI152970-01KAUVAR, LAWRENCE MICHAELTRELLIS BIOSCIENCE, INC., CA$299,667ZAI1
2020A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine1U44AI152995-01AMANNA, IAN JAMESSLIFKA, MARK KNAJIT TECHNOLOGIES, INC., OR$290,420ZAI1
2019A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease1U44AI134590-01A1MURRAY, JOSEPH ASYAGE, JACK A.IMMUNOGENICS, LLC, CA$299,089ZAI1
2019A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine1U44AI145791-01AMANNA, IAN JAMESSLIFKA, MARK KNAJIT TECHNOLOGIES, INC., OR$292,140ZAI1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.